- Home
- ANNX vs RGNX Comparison
ANNX vs RGNX Comparison
Compare ANNX & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANNX
- RGNX
- Stock Information
- Founded
- ANNX 2011
- RGNX 2008
- Country
- ANNX United States
- RGNX United States
- Employees
- ANNX N/A
- RGNX N/A
- Industry
- ANNX Biotechnology: Pharmaceutical Preparations
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ANNX Health Care
- RGNX Health Care
- Exchange
- ANNX Nasdaq
- RGNX Nasdaq
- Market Cap
- ANNX 362.4M
- RGNX 387.0M
- IPO Year
- ANNX 2020
- RGNX 2015
- Fundamental
- Price
- ANNX $1.60
- RGNX $7.52
- Analyst Decision
- ANNX Strong Buy
- RGNX Strong Buy
- Analyst Count
- ANNX 5
- RGNX 8
- Target Price
- ANNX $18.67
- RGNX $31.75
- AVG Volume (30 Days)
- ANNX 1.6M
- RGNX 1.1M
- Earning Date
- ANNX 05-20-2025
- RGNX 05-12-2025
- Dividend Yield
- ANNX N/A
- RGNX N/A
- EPS Growth
- ANNX N/A
- RGNX N/A
- EPS
- ANNX N/A
- RGNX N/A
- Revenue
- ANNX N/A
- RGNX $83,328,000.00
- Revenue This Year
- ANNX N/A
- RGNX $285.14
- Revenue Next Year
- ANNX N/A
- RGNX N/A
- P/E Ratio
- ANNX N/A
- RGNX N/A
- Revenue Growth
- ANNX N/A
- RGNX N/A
- 52 Week Low
- ANNX $1.29
- RGNX $5.04
- 52 Week High
- ANNX $7.85
- RGNX $17.52
- Technical
- Relative Strength Index (RSI)
- ANNX 38.84
- RGNX 46.69
- Support Level
- ANNX $1.62
- RGNX $6.89
- Resistance Level
- ANNX $2.01
- RGNX $10.59
- Average True Range (ATR)
- ANNX 0.13
- RGNX 0.79
- MACD
- ANNX 0.01
- RGNX -0.19
- Stochastic Oscillator
- ANNX 0.00
- RGNX 20.67
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.